Literature DB >> 17026483

AMP-activated protein kinase: Role in metabolism and therapeutic implications.

Greg Schimmack1, Ralph A Defronzo, Nicolas Musi.   

Abstract

AMP-activated protein kinase (AMPK) is an enzyme that works as a fuel gauge which becomes activated in situations of energy consumption. AMPK functions to restore cellular ATP levels by modifying diverse metabolic and cellular pathways. In the skeletal muscle, AMPK is activated during exercise and is involved in contraction-stimulated glucose transport and fatty acid oxidation. In the heart, AMPK activity increases during ischaemia and functions to sustain ATP, cardiac function and myocardial viability. In the liver, AMPK inhibits the production of glucose, cholesterol and triglycerides and stimulates fatty acid oxidation. Recent studies have shown that AMPK is involved in the mechanism of action of metformin and thiazolidinediones, and the adipocytokines leptin and adiponectin. These data, along with evidence that pharmacological activation of AMPK in vivo improves blood glucose homeostasis, cholesterol concentrations and blood pressure in insulin-resistant rodents, make this enzyme an attractive pharmacological target for the treatment of type 2 diabetes, ischaemic heart disease and other metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17026483     DOI: 10.1111/j.1463-1326.2005.00561.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  40 in total

1.  AMP-activated protein kinase deficiency exacerbates aging-induced myocardial contractile dysfunction.

Authors:  Subat Turdi; Xiujuan Fan; Ji Li; Junxing Zhao; Anna F Huff; Min Du; Jun Ren
Journal:  Aging Cell       Date:  2010-05-10       Impact factor: 9.304

Review 2.  New therapies for diabesity.

Authors:  Clifford J Bailey
Journal:  Curr Diab Rep       Date:  2009-10       Impact factor: 4.810

Review 3.  Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling.

Authors:  Rosalind A Coleman; Douglas G Mashek
Journal:  Chem Rev       Date:  2011-06-01       Impact factor: 60.622

4.  Does diabetes therapy influence the risk of cancer?

Authors:  U Smith; E A M Gale
Journal:  Diabetologia       Date:  2009-09       Impact factor: 10.122

Review 5.  Management of Severe Insulin Resistance in Patients with Type 1 Diabetes.

Authors:  Rebecca Schechter; Sirimon Reutrakul
Journal:  Curr Diab Rep       Date:  2015-10       Impact factor: 4.810

6.  Inhibitory effect of esculetin on free-fatty-acid-induced lipid accumulation in human HepG2 cells through activation of AMP-activated protein kinase.

Authors:  Yeaji Park; Jeehye Sung; Jinwoo Yang; Hyeonmi Ham; Younghwa Kim; Heon-Sang Jeong; Junsoo Lee
Journal:  Food Sci Biotechnol       Date:  2017-02-28       Impact factor: 2.391

7.  Astragaloside IV attenuates free fatty acid-induced ER stress and lipid accumulation in hepatocytes via AMPK activation.

Authors:  Bing Zhou; Dan-Li Zhou; Xiao-Hong Wei; Rong-Yu Zhong; Jie Xu; Liao Sun
Journal:  Acta Pharmacol Sin       Date:  2017-03-27       Impact factor: 6.150

Review 8.  The use of metformin in type 1 diabetes: a systematic review of efficacy.

Authors:  S Vella; L Buetow; P Royle; S Livingstone; H M Colhoun; J R Petrie
Journal:  Diabetologia       Date:  2010-01-08       Impact factor: 10.122

9.  Elevated oxygen consumption rate in response to acute low-glucose stress: Metformin restores rate to normal level.

Authors:  Emmanuel D Williams; Steven C Rogers; Xiaomin Zhang; Gohar Azhar; Jeanne Y Wei
Journal:  Exp Gerontol       Date:  2015-08-07       Impact factor: 4.032

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.